12 Feb 2021 07:00
12 February 2021 ASX Code: MXC LSE Code: MXC | MGC Pharma Investor Presentation Today - Friday 12th February 2021 |
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC, 'MGC Pharma' or 'the Company'), the first and currently only medicinal cannabis company to be listed on the LSE, will be presenting at an investor webinar being hosted jointly by Turner Pope Investments and Vox Markets.
Roby Zomer, CEO and Managing Director, and Brett Mitchell, Executive Chairman, will be presenting and answering questions from attendees.
MGC Pharma is a European based and dual listed bio-pharma company specialising in the production and development of phytocannabinoid-derived medicines.
The webinar will take place at 10am GMT (9pm Sydney) today, Friday 12th February 2021. Please register your interest at https://voxmarkets.brand.live/c/vox-markets-and-turner-pope-webinar-friday-february-12th.
--Ends--
For further information please contact:
UK PR Tavistock - Tavistock Charlies Vivian +44 20 7920 3150 Charles.Vivian@tavistock.co.uk
PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) +61 412 277 377 Rod.Hinchcliffe@mcpartners.com.au | MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au
Corporate Broker - Turner Pope Investments Andy Thacker Andy.Thacker@TurnerPope.com Zoe Alexander +44 203 657 0050 |
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. The most advanced of these is ArtemiCTM, which recently successfully completed Phase II trials as a potential aid to the recovery of moderate COVID-19 patients.
Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.
MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma